Zheng Quan Ri Bao·2025-10-24 22:57Core Viewpoint - The company has completed a share buyback program, reducing its total share capital and enhancing shareholder value through strategic financial management [5]. Financial Data - The company reported that it has not undergone an audit for the third-quarter financial statements [3]. - The total number of shares repurchased was 5,472,559, which accounts for 0.98% of the company's total share capital, with a total expenditure of 120 million yuan [5]. - Following the share buyback, the total share capital decreased from 556,890,744 shares to 551,418,185 shares, and the registered capital changed from 556,890,744 yuan to 551,418,185 yuan [5]. Shareholder Information - The company confirmed that there were no changes in the major shareholders or the top ten shareholders due to share lending activities [4]. - The company’s actual controller changed from the Fuling District State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group Corporation, with the ultimate controller being the State-owned Assets Supervision and Administration Commission of the State Council [6][7]. Other Important Information - The company has committed to resolving competition issues with its major shareholder, China National Pharmaceutical Group, by April 14, 2026, through various strategic measures [6][7].